We have located links that may give you full text access.
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Review
Dermatomyositis induced by drug therapy: a review of case reports.
Journal of the American Academy of Dermatology 2008 November
BACKGROUND: Drugs have occasionally been implicated in dermatomyositis (DM) onset.
OBJECTIVE: We sought to review case reports of drug-induced DM.
METHODS: Articles were gathered from MEDLINE and bibliographies of acquired reports. Causality was assessed using World Health Organization criteria. Clinical characteristics, management, and resolution were examined.
RESULTS: In 70 reported cases, 50% of patients were female and the median age was 57 years. Hydroxyurea was implicated in 51% of cases. All cases had pathognomonic (76%) or compatible (24%) cutaneous findings. Hydroxyurea cases lacked myositis, but myositis was described in 79.4% of nonhydroxyurea cases. Drug causality was probable (25.7%) or possible (74.3%), but not certain in any case. Most patients had underlying pathology associated with DM (44% had malignancy; 16% had rheumatoid arthritis). Of the sample, 84.3% had improvement of DM after discontinuation of the drug.
LIMITATIONS: Case reports may emphasize unusual findings.
CONCLUSIONS: Further work is needed to differentiate drug effects from underlying, predisposing factors.
OBJECTIVE: We sought to review case reports of drug-induced DM.
METHODS: Articles were gathered from MEDLINE and bibliographies of acquired reports. Causality was assessed using World Health Organization criteria. Clinical characteristics, management, and resolution were examined.
RESULTS: In 70 reported cases, 50% of patients were female and the median age was 57 years. Hydroxyurea was implicated in 51% of cases. All cases had pathognomonic (76%) or compatible (24%) cutaneous findings. Hydroxyurea cases lacked myositis, but myositis was described in 79.4% of nonhydroxyurea cases. Drug causality was probable (25.7%) or possible (74.3%), but not certain in any case. Most patients had underlying pathology associated with DM (44% had malignancy; 16% had rheumatoid arthritis). Of the sample, 84.3% had improvement of DM after discontinuation of the drug.
LIMITATIONS: Case reports may emphasize unusual findings.
CONCLUSIONS: Further work is needed to differentiate drug effects from underlying, predisposing factors.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices 
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app